These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 28821236)

  • 21. Comparison of two intravitreal ranibizumab treatment schedules for neovascular age-related macular degeneration.
    Gupta B; Adewoyin T; Patel SK; Sivaprasad S
    Br J Ophthalmol; 2011 Mar; 95(3):386-90. PubMed ID: 20693484
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study.
    Brown DM; Michels M; Kaiser PK; Heier JS; Sy JP; Ianchulev T;
    Ophthalmology; 2009 Jan; 116(1):57-65.e5. PubMed ID: 19118696
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vitreomacular Interface after Anti-Vascular Endothelial Growth Factor Injections in Neovascular Age-Related Macular Degeneration.
    Veloso CE; Kanadani TM; Pereira FB; Nehemy MB
    Ophthalmology; 2015 Aug; 122(8):1569-72. PubMed ID: 26038338
    [TBL] [Abstract][Full Text] [Related]  

  • 24. TREATMENT OUTCOMES FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION PATIENTS WITH INITIAL VISION BETTER THAN 20/40 USING A TREAT-AND-EXTEND REGIMEN.
    Rahimy E; Rayess N; Ho AC; Regillo CD
    Retina; 2016 May; 36(5):875-80. PubMed ID: 26630316
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association between choroidal thickness and the response to intravitreal ranibizumab injection in age-related macular degeneration.
    Shin JY; Kwon KY; Byeon SH
    Acta Ophthalmol; 2015 Sep; 93(6):524-32. PubMed ID: 25581639
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pre-Existing RPE Atrophy and Defects in the External Limiting Membrane Predict Early Poor Visual Response to Ranibizumab in Neovascular Age-Related Macular Degeneration.
    Zandi S; Weisskopf F; Garweg JG; Pfister IB; Pruente C; Sutter F; Hatz K
    Ophthalmic Surg Lasers Imaging Retina; 2017 Apr; 48(4):326-332. PubMed ID: 28419398
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Results of patients with neovascular age-related macular degeneration managed by a treat-extend-stop protocol without recurrence.
    Adrean SD; Chaili S; Pirouz A; Grant S
    Graefes Arch Clin Exp Ophthalmol; 2021 Dec; 259(12):3665-3673. PubMed ID: 34251484
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Factors influencing macular atrophy growth rates in neovascular age-related macular degeneration treated with ranibizumab or aflibercept according to an observe-and-plan regimen.
    Mantel I; Zola M; De Massougnes S; Dirani A; Bergin C
    Br J Ophthalmol; 2019 Jul; 103(7):900-905. PubMed ID: 30166328
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Predictive value of spectral-domain optical coherence tomography features in assessment of visual prognosis in eyes with neovascular age-related macular degeneration treated with ranibizumab.
    Mathew R; Richardson M; Sivaprasad S
    Am J Ophthalmol; 2013 Apr; 155(4):720-6, 726.e1. PubMed ID: 23317653
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Progression of retinal pigment epithelial atrophy in antiangiogenic therapy of neovascular age-related macular degeneration.
    Schütze C; Wedl M; Baumann B; Pircher M; Hitzenberger CK; Schmidt-Erfurth U
    Am J Ophthalmol; 2015 Jun; 159(6):1100-1114.e1. PubMed ID: 25769245
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk factors for geographic atrophy after intravitreal ranibizumab injections for retinal angiomatous proliferation.
    Cho HJ; Yoo SG; Kim HS; Kim JH; Kim CG; Lee TG; Kim JW
    Am J Ophthalmol; 2015 Feb; 159(2):285-92.e1. PubMed ID: 25447115
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictive factors of visual and anatomical outcome after intravitreal bevacizumab treatment of neovascular age-related macular degeneration: an optical coherence tomography study.
    Singh RP; Fu EX; Smith SD; Williams DR; Kaiser PK
    Br J Ophthalmol; 2009 Oct; 93(10):1353-8. PubMed ID: 19556212
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effectiveness of intravitreal ranibizumab for the treatment of neovascular age-related macular degeneration in a Canadian retina practice: a retrospective review.
    Bandukwala T; Muni RH; Schwartz C; Eng KT; Kertes PJ
    Can J Ophthalmol; 2010 Dec; 45(6):590-5. PubMed ID: 21135894
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combined fluorescein angiography and spectral-domain optical coherence tomography imaging of classic choroidal neovascularization secondary to age-related macular degeneration before and after intravitreal ranibizumab injections.
    Coscas F; Querques G; Forte R; Terrada C; Coscas G; Souied EH
    Retina; 2012 Jun; 32(6):1069-76. PubMed ID: 22466476
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The neovascular age-related macular degeneration database: report 2: incidence, management, and visual outcomes of second treated eyes.
    Zarranz-Ventura J; Liew G; Johnston RL; Xing W; Akerele T; McKibbin M; Downey L; Natha S; Chakravarthy U; Bailey C; Khan R; Antcliff R; Armstrong S; Varma A; Kumar V; Tsaloumas M; Mandal K; Bunce C; Tufail A;
    Ophthalmology; 2014 Oct; 121(10):1966-75. PubMed ID: 24953791
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Results of one-year's treatment with ranibizumab for exudative age-related macular degeneration in a clinical setting.
    Cohen SY; Dubois L; Tadayoni R; Fajnkuchen F; Nghiem-Buffet S; Delahaye-Mazza C; Guiberteau B; Quentel G
    Am J Ophthalmol; 2009 Sep; 148(3):409-13. PubMed ID: 19477713
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A paradigm shift in imaging biomarkers in neovascular age-related macular degeneration.
    Schmidt-Erfurth U; Waldstein SM
    Prog Retin Eye Res; 2016 Jan; 50():1-24. PubMed ID: 26307399
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study.
    Lalwani GA; Rosenfeld PJ; Fung AE; Dubovy SR; Michels S; Feuer W; Davis JL; Flynn HW; Esquiabro M
    Am J Ophthalmol; 2009 Jul; 148(1):43-58.e1. PubMed ID: 19376495
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Risk of geographic atrophy in age-related macular degeneration patients treated with intravitreal anti-VEGF agents.
    Gemenetzi M; Lotery AJ; Patel PJ
    Eye (Lond); 2017 Jan; 31(1):1-9. PubMed ID: 27716750
    [TBL] [Abstract][Full Text] [Related]  

  • 40. ROLE OF ADDITIONAL DEXAMETHASONE FOR THE MANAGEMENT OF PERSISTENT OR RECURRENT NEOVASCULAR AGE-RELATED MACULAR DEGENERATION UNDER RANIBIZUMAB TREATMENT.
    Rezar-Dreindl S; Eibenberger K; Buehl W; Georgopoulos M; Weigert G; Krall C; Dunavoelgyi R; Schmidt-Erfurth U; Sacu S
    Retina; 2017 May; 37(5):962-970. PubMed ID: 27575409
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.